AbbVie Slashes Humira Price 86% on Trump's Drug Site—After White House Threatened 100% Tariffs

AbbVie's mega-blockbuster arthritis drug Humira will be available on the Trump administration's TrumpRx platform for around $950—an 86% discount from its typical $6,900 price tag for uninsured patients, according to CBS News reporting on Tuesday.

The discount is part of a deal AbbVie struck with the White House in January: in exchange for participating in TrumpRx and committing $100 billion to research and manufacturing, the pharmaceutical giant secured what it thought was an exemption from tariffs and future "price mandates" the government might impose.

That exemption turned out to be worth less than promised. When President Donald Trump announced tariffs up to 100% on pharmaceutical imports last Friday, multiple companies with existing exemption agreements—including AbbVie—discovered they would still face the levies. The tariff threat appears to have been the leverage that forced AbbVie to finalize its pricing on TrumpRx.

How TrumpRx Actually Works

The discounted prices on TrumpRx apply only to patients without insurance coverage or those whose plans don't cover the specific medications. Insured patients already typically pay lower prices through their plans and won't benefit from the platform.

In addition to Humira, AbbVie will sell its hypothyroidism drug Synthroid and eye drops Combigan and Alphagan at discounts on the site. The company announced its TrumpRx participation in January but didn't disclose pricing until this week—after the tariff announcement.

TrumpRx launched in February as part of the administration's push to bring U.S. prescription drug costs down to levels comparable to other developed countries under Trump's "Most Favored Nation" mandate. Several pharmaceutical giants including Pfizer and AstraZeneca have offered discounted products on the direct-to-consumer platform.

The Tariff Bait-and-Switch

The timing reveals how the Trump administration is using trade policy as a cudgel. Companies were told they could secure exemptions by participating in TrumpRx and making domestic investment pledges. But when Trump announced the 100% pharma tariffs on Friday, many of those exemption deals evaporated.

This pattern—promising regulatory relief in exchange for corporate commitments, then imposing penalties anyway—raises questions about whether these agreements are genuine policy tools or simply mechanisms to extract favorable headlines and campaign-season announcements from major corporations.

For AbbVie, the calculus appears straightforward: offer steep discounts to a relatively small segment of uninsured patients on a government platform, announce a massive manufacturing pledge, and hope to avoid tariffs that could disrupt the company's entire supply chain. When the tariffs came anyway, AbbVie was already locked into the deal.

Who Actually Benefits

Humira, used to treat rheumatoid arthritis and other autoimmune conditions, has been one of the world's top-selling drugs for years. Its list price has climbed steadily even as biosimilar competitors entered the market. The $950 TrumpRx price represents real savings for uninsured patients who would otherwise pay full freight—but it does nothing for the millions of Americans whose insurance plans already negotiate lower prices or for those whose plans simply don't cover Humira at all.

The Trump administration will likely tout the discount as evidence its tariff threats and direct negotiation tactics work. But the underlying dynamic is more complicated: pharmaceutical companies are making calculated business decisions to participate in a government platform that serves a narrow patient population, while the broader issues driving high drug prices—patent monopolies, pharmacy benefit manager practices, and lack of price negotiation for Medicare—remain largely untouched.

Meanwhile, the tariff threat that forced this deal could raise costs across the pharmaceutical supply chain, potentially increasing prices for other medications not featured on TrumpRx. The administration is effectively using trade policy to generate PR wins on a handful of high-profile drugs while creating economic uncertainty that could harm patients in less visible ways.

AbbVie did not immediately respond to requests for comment on whether the company considers its tariff exemption still valid or how it plans to navigate the new trade landscape.